GlassScriptPhysician profile
Alina Rivera
NPI 1962809368
$2,010.03
in general payments reported to CMS, 2019-2025
22 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $149 · 2021: $197 · 2022: $376 · 2023: $276 · 2024: $156 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $569.56 | 2019-2023 | Rybelsus |
| Amarin Pharma, INC. | $304.50 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.57 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $200.76 | 2022-2025 | Jardiance, Mounjaro |
| Amgen INC. | $100.39 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $73.69 | 2022-2024 | Arexvy, Shingrix |
| Gilead Sciences, INC. | $73.50 | 2023-2025 | Veklury |
| Abbvie INC. | $60.39 | 2021-2022 | |
| Vivus LLC | $49.11 | 2021-2023 | Qsymia |
| Exact Sciences Corporation | $44.89 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Horizon Therapeutics Plc | $44.06 | 2022 | |
| Currax Pharmaceuticals LLC | $37.07 | 2020-2023 | Contrave, Onzetra Xsail |
| Regeneron Healthcare Solutions, INC. | $24.42 | 2019 | |
| Pfizer INC. | $22.65 | 2024 | |
| Smith+Nephew, INC. | $18.82 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aprecia Pharmaceuticals, LLC | $17.43 | 2023 | Spritam |
| Novartis Pharmaceuticals Corporation | $16.32 | 2022 | |
| Abbott Laboratories | $16.27 | 2024 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $14.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.37 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alina Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.